96. クローン病 Crohn disease Clinical trials / Disease details


臨床試験数 : 2,442 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

  
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03220841
(ClinicalTrials.gov)
October 9, 20176/7/2017Stricture Definition and Treatment (STRIDENT) Drug Therapy StudyStricture Definition and Treatment (STRIDENT) Drug Therapy StudyCrohn Disease;Inflammatory Bowel Diseases;Stricture; BowelDrug: Adalimumab Injection;Drug: Thiopurine;Procedure: Endoscopic balloon dilatationSt Vincent's Hospital MelbourneAustralasian Gastro Intestinal Research Foundation;AbbVieActive, not recruiting18 YearsN/AAll78Phase 4Australia
2NCT03185611
(ClinicalTrials.gov)
May 18, 201711/6/2017Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Recurrence in Crohn's DiseaseEffectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Endoscopic Recurrence in Crohn's Disease Patients With Risk Factor for Recurrence: A Multicenter Randomized Controlled TrialCrohn DiseaseDrug: Rifaximin;Drug: AzathioprineSixth Affiliated Hospital, Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University;Peking Union Medical College Hospital;Xijing Hospital;Shanghai 10th People's Hospital;RenJi Hospital;Sir Run Run Shaw HospitalRecruiting18 Years65 YearsAll120Phase 3China
3EUCTR2016-001638-84-NL
(EUCTR)
08/07/201617/05/2016Thiopurines with Low Dose Allopurinol: a prospective one way cross-over studyThiopurines with Low Dose Allopurinol: a prospective one way cross-over study - ThiLDA-study Crohn's disease & Colitis Ulcerosa;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Trade Name: Allopurinol Sandoz 100 mg, tabletten
INN or Proposed INN: ALLOPURINOL
INN or Proposed INN: ALLOPURINOL
Meander Medical CenterNULLNot RecruitingFemale: yes
Male: yes
Phase 4Netherlands
4NCT02255370
(ClinicalTrials.gov)
December 201419/9/2014Curcumin Associated With Thiopurin in the Prevention of Post-op Recurrence in Crohn DiseaseControlled, Randomized, Double Blind Study, Comparing Curcumin to Thiopurines in the Prevention of Post-op Recurrence in Crohn DiseaseCrohn's DiseaseDrug: CurcuminUniversity Hospital, Clermont-Ferrand3i nature;Naturopôle Nutrition santéCompleted18 YearsN/AAll61Phase 3France
5NCT02453607
(ClinicalTrials.gov)
November 17, 201421/5/2015The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's DiseaseThe Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's DiseaseInflammatory Bowel Disease;Crohn's DiseaseDrug: Infliximab;Drug: thiopurineErnest SeidmanUniversity of Toronto;University of Calgary;University of AlbertaRecruiting18 Years70 YearsAll225N/ACanada
6EUCTR2014-000261-51-FR
(EUCTR)
04/11/201428/08/2015Randomized, controlled, double bind study, comparing curcumin to placebo, associated with thiopurines, in the the prevention of post-operative Crohn's desease relapsePOPCUR : a randomized, controlled, double bind study, comparing curcuma to placebo, associated with thiopurines, in the prevention of post-operative Crohn's disease recurrence - POPCUR Crohn's Disease
MedDRA version: 18.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Curcuma
Other descriptive name: CURCUMA LONGA RHIZOMA
CHU de Clermont-FerrandNULLNot RecruitingFemale: yes
Male: yes
122Phase 3France
7JPRN-UMIN000012790
2014/02/0101/02/2014Prospective Pilot study of Infliximab Dose-intensification determined by Capsule Endoscopic Evaluation of Small Intestinal Involvements in Patients with Crohn's DiseaseProspective Pilot study of Infliximab Dose-intensification determined by Capsule Endoscopic Evaluation of Small Intestinal Involvements in Patients with Crohn's Disease - CADELLAC study Crohn's diseasedose intensification of 10mg/kg infliximab with additional treatment with thiopurines in case of aggravation at 6 monthsSaitama Medical centerNULLComplete: follow-up complete20years-old65years-oldMale and Female20Not selectedJapan
8NCT01802593
(ClinicalTrials.gov)
February 201324/12/2012Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine FailurePhase 4, Open Label Multicenter Randomized Controlled Trial. Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Immunomodulator FailureCrohn's DiseaseDrug: AZATHIOPRINE or METHOTREXATEProf. Arie LevineNULLTerminated6 Years18 YearsBoth20Phase 4Israel
9NCT00167882
(ClinicalTrials.gov)
July 20059/9/2005The Influence of 5–Aminosalicylates on Thiopurine Metabolite LevelsCrohn's Disease;Ulcerative Colitis;Inflammatory Bowel DiseaseDrug: 5-aminosalicylate (Pentasa, Ferring)VU University Medical CenterNULLCompleted18 Years70 YearsBoth24Phase 4Netherlands